Mineralys Therapeutics MLYS
NASDAQ MLYS
$15.52 -0.29 (-1.83%)
At close: Nov 10, 2026 · 4:00 PM EST

Mineralys Therapeutics (MLYS) Total Debt (2026)

Updated

Mineralys Therapeutics (MLYS) reported Total Debt of $98.27 million for Q3 2026, up 0.7% from the prior quarter.

Analysis

Mineralys Therapeutics (MLYS) Total Debt (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 49.50 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 44.65 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 80.90 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 53.78 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -6.68 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 54.01 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 26.23 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 62.67 Bn
10 Mineralys Therapeutics 1.37 Bn -1.21 Bn - 98.27 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 98.27 Mn
Jun 30, 2026 97.62 Mn
API Access

Mineralys Therapeutics Total Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-debt&ticker=MLYS&period=max&api_key=YOUR_API_KEY